Catalyst Watchlist
This Month's Biotech Catalyst Watchlist
Top 10 catalysts retail biotech investors should understand this month — with plain-English trial context, risk flags, and what success or failure could mean for the stock.
Phase 3 readouts
Which endpoint matters, what success has to prove, and why the stock could gap either direction.
FDA/PDUFA decisions
Decision windows, label-risk questions, advisory committee context, and follow-up dates to monitor.
Financing risk
Cash runway, dilution pressure, and whether a positive catalyst may still be followed by a raise.
What the Pro watchlist includes
- Ticker + catalyst: the company, event type, expected timing, and source links.
- Why it matters: whether the event can change valuation, pipeline credibility, or financing terms.
- What success looks like: primary endpoint, safety bar, and the cleanest bullish interpretation.
- What failure looks like: missed endpoints, weak durability, subgroup problems, or label-limiting safety.
- Risk flags: endpoint risk, safety risk, comparator risk, enrollment risk, and dilution/financing risk.
Free sample
Get the abbreviated weekly briefing
Start with a free sample of the catalyst brief. Pro adds the full ranked watchlist, risk flags, and memo archive.
Free weekly biotech briefing. No spam. By subscribing, you agree to our Privacy Policy and Terms.
ClinicalInvestor Pro
Know what to watch before the readout hits.
Pro is built for investors who want a repeatable catalyst checklist, not another noisy stock feed.
Start tracking catalystsEducational use only. ClinicalInvestor does not provide personalized financial advice or recommendations to buy or sell securities.